Active substance: artesunate – sulfamethoxypyrazine/pyrimethamine (SMP) as a fixed dose combination
Form : tablets
Dose per tablet :
Co-Arinate Enfant : 100 mg artesunate, 250 mg sulfamethoxypyrazine and 12,5 mg pyrimethamine.
Co-Arinate Adulte : 200 mg artesunate, 500 mg sulfamethoxypyrazine and 25 mg pyrimethamine.
Packaging : Box with 3 tablet blisters
Co-Arinate Junior : children from 9kg to 35 kg ( 1 up to 13 y)
Co-Arinate Adult : adults and bigger children ( >35kg) (14 y and older)
Further dose adaptations may be necessary for adults > 80 kg.
Co‐Arinate® is used as curative treatment for all forms of malaria, including severe malaria caused by multi drug‐resistant strains of Plasmodium falciparum.
The dose for this treatment is based on body weight at 4 mg / kg of Artesunate
combined with Sulfamethoxypyrazine and Pyrimethamine.
Three consecutive intakes of this dose must be given during 48 hours:
To avoid relapse, the full course of treatment should be completed.
If vomiting occurs within 30 minutes of taking the tablet, the full dose should be re-administered.
If vomiting occurs within one hour, half a dose should be re-administered.
Prescription drugs. Please contact your doctor.
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.